Exciva is a clinical-stage biopharmaceutical company focused on developing novel therapies for behavioral symptoms associated with Alzheimer's disease (AD).
The company is advancing Deraphan, a combination therapy comprising two clinically validated compounds including a new chemical entity, aiming to provide a differentiated safety and efficacy profile for agitation in AD patients.
Leadership & Board
Current Number of Employees7
Current LinkedIn Followers763
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$51M
Total Amount Raised$51M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$51M
Latest Funding Amount$51M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Exciva had 7 employees as of September 7, 2026. The number of employees increased by 0 (0.00%) week-over-week.
7Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Exciva had 763 followers as of September 7, 2026. The number of followers increased by 2 (0.26%) week-over-week.
763Latest Followers Count
2(0.26%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.